Little Known Facts About ABBV-744 as a potential therapeutic option for aggressive cancers.
In Segment C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, participants will get ABBV-744 and ruxolitinib. Participants will obtain treatment right until disorder progression or the members are unable to tolerate the study drugs.Ubiquitin-relevant proteins that control The steadiness of essential super enhancer-mediated pro